Press Releases May 18, 2026 04:15 PM

Certara to Participate in Upcoming Investor Conferences

Certara announces participation in multiple upcoming investor conferences with live webcasts.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CERT

Certara, Inc., a leader in model-informed drug development, will participate in several investor conferences including RBC CM Global Healthcare, William Blair’s Growth Stock, and Jefferies Global Healthcare Conferences. The company will provide live webcasts of select events accessible through its investor relations website.

Certara to Participate in Upcoming Investor Conferences
CERT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Certara engages actively with investors through scheduled participation in prominent healthcare and growth stock conferences.
  • Live webcasts available for select conference presentations, improving transparency and investor communication.
  • The company positions itself as a global leader in biosimulation software and services for drug development, serving a broad client base across biopharmaceutical firms, academia, and regulatory bodies.

RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

  • RBC CM Global Healthcare Conference
    Date and Time: Tuesday, May 19 at 9:30 a.m. ET
  • William Blair’s 46th Annual Growth Stock Conference
    Date: Tuesday, June 2
  • Jefferies Global Healthcare Conference
    Date: Wednesday, June 3 at 1:20 p.m. ET

Live webcasts for the RBC and Jefferies conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Alyssa Horowitz
certara@pancomm.com


Risks

  • Market and investor response to conference presentations may be uncertain and could impact stock volatility.
  • The company's performance is highly dependent on the pharmaceutical and healthcare sectors, which can be affected by regulatory changes and market competition.
  • Technology advancements or disruptions in biosimulation and drug development could impact Certara's competitive position.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026